Harvard MD: The Truth About Peptides And Longevity Medicine
Harvard MD: The Peptide Boom Is Here.. But Is Medicine Ready?
In this episode of Return on Health, Niko and Miguel speak with Dr. Anand Vinjamoori, Harvard Medical School and Harvard Business School trained physician, former founding Chief Medical Officer at Modern Age, advisor to Superpower, and founder of Next Generation Medicine.
Together, they discuss why longevity medicine is booming while many companies still struggle to build sustainable businesses, why peptides may become one of the next major waves in health optimization, and why the future of biomarkers will likely require a much more individualized and data-driven approach.
This episode covers:
The peptide boom and why it matters
Why longevity businesses often fail
What biomarkers can and cannot tell us
Dr. Anand explains why the current medical evidence system may be too slow for the next generation of therapies, how real-world data and patient registries could help close the evidence gap, and why biomarkers should be used with nuance rather than treated as absolute truth. He also shares his view on overhyped interventions, the role of exercise, and the cultural differences between American optimization culture and European lifestyle rhythms.
Key topics
Longevity medicine and market timing
The business challenges behind longevity clinics
Customer acquisition and why messaging matters
The rise of peptides in health optimization
Evidence gaps, real-world data, and patient registries
Personalized medicine and individual risk assessment
Biomarkers, multi-omics, and biological individuality
Why HBA1c can be overinterpreted
Exercise as one of the strongest health interventions
Cold plunges and the problem of overapplied hormesis
European lifestyle culture vs. American optimization culture
Chapters
00:00 The Longevity Paradox
01:03 Building Modern Age and the Early Longevity Market
05:04 Personal Motivations Behind Longevity Medicine
07:57 What Patients Actually Want From Longevity Care
11:39 Why Many Longevity Businesses Struggle
15:12 How Customer Preferences Have Changed
18:21 Peptides as the Next Big Wave
19:07 Peptides, Regulation, and Medical Experimentation
24:24 The Evidence Gap in Peptide Use
30:58 Why Medicine Needs Better Risk Assessment
36:59 Biomarkers and Biological Ground Truth
44:20 Multi-Omics and the Future of Measurement
48:35 Which Biomarkers Are Useful — And Which Are Noise?
52:42 Culture, Lifestyle, and Health Optimization
55:45 Lightning Round: Metrics, Interventions, and Healthcare Reform
Guest
Dr. Anand VinjamooriHarvard Medical School and Harvard Business School trained physician, former founding Chief Medical Officer at Modern Age, advisor to Superpower, and founder of Next Generation Medicine.
Guest links
LinkedIn: https://www.linkedin.com/in/vinjamoori/ [https://www.linkedin.com/in/vinjamoori/]
Next Generation Medicine: https://www.nextgenerationmedicine.co/ [https://www.nextgenerationmedicine.co/]
Superpower: https://www.linkedin.com/company/superpower/posts/?feedView=all [https://www.linkedin.com/company/superpower/posts/?feedView=all]
Listen now
Return on Health is available wherever you get your podcasts.
If you enjoyed this episode, leaving a 5-star rating on Spotify helps us bring more honest conversations about health, longevity, and medicine to more people.